Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Or; Yat Sun
Address:
Watertown, MA
No. of patents:
79
Patents:


1 2










Patent Number Title Of Patent Date Issued
RE42375 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors May 17, 2011
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds
8575119 2'-chloroacetylenyl substituted nucleoside derivatives November 5, 2013
The present invention relates to 2'-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): ##STR00001## As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnorm
8283309 Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors October 9, 2012
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8273720 6,11-bicyclolides: bridged biaryl macrolide derivatives September 25, 2012
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
8273709 Triazole-containing macrocyclic HCV serine protease inhibitors September 25, 2012
The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compou
8268777 Oximyl macrocyclic derivatives September 18, 2012
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8268776 Macrocylic oximyl hepatitis C protease inhibitors September 18, 2012
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8263549 C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors September 11, 2012
The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8242156 Linked dibenzimidazole derivatives August 14, 2012
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with
8236807 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors August 7, 2012
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds
8222203 Macrocyclic oximyl hepatitis C serine protease inhibitors July 17, 2012
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8221737 Hepatitis C virus inhibitors July 17, 2012
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with
8211891 Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors July 3, 2012
The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the p
8193346 Process for making macrocyclic oximyl hepatitis C protease inhibitors June 5, 2012
The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.
8188132 Linked dibenzimidazole derivatives May 29, 2012
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with
8178531 Antiviral agents May 15, 2012
The present invention relates to antiviral compounds of formula (I), ##STR00001## compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatmen
8163707 4'-allene-substituted nucleoside derivatives April 24, 2012
The present invention discloses compounds of formula (I), or its .beta.-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: ##STR00001## which inhibit, preventing or treating abnormal cellular proliferation and/o
8124584 Macrocyclic hepatitis C serine protease inhibitors February 28, 2012
The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly th
8101643 Benzimidazole derivatives January 24, 2012
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with
8101567 Heteroaryl-containing tripeptide HCV serine protease inhibitors January 24, 2012
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
8030307 Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease October 4, 2011
The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
7919627 Processes for the preparation of hydroxylamines April 5, 2011
The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT
7910587 Quinoxalinyl dipeptide hepatitis C virus inhibitors March 22, 2011
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
7910558 Bridged macrocyclic compounds and processes for the preparation thereof March 22, 2011
The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent optionally in the presence of a catalyst, thereby
7906513 Hydrazide-containing hepatitis C serine protease inhibitors March 15, 2011
The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. C
7842813 Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine November 30, 2010
The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts
7728148 Acyclic oximyl hepatitis C protease inhibitors June 1, 2010
The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the p
7718769 Tri-peptide hepatitis C serine protease inhibitors May 18, 2010
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
7718612 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors May 18, 2010
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present inven
7687459 Arylalkoxyl hepatitis C virus protease inhibitors March 30, 2010
The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds o
7662779 Triazolyl macrocyclic hepatitis C serine protease inhibitors February 16, 2010
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds o
7635683 Quinoxalinyl tripeptide hepatitis C virus inhibitors December 22, 2009
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the
7622452 C-9 alkenylidine bridged macrolides November 24, 2009
The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned
7605126 Acylaminoheteroaryl hepatitis C virus protease inhibitors October 20, 2009
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds
7589067 6, 11-bridged tricyclic macrolides September 15, 2009
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
7582605 Phosphorus-containing hepatitis C serine protease inhibitors September 1, 2009
The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the
7566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors July 28, 2009
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds
7563877 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synt July 21, 2009
The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]oxazol-5-yl)methyl h
7538225 Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine May 26, 2009
The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT
7468419 Cyclosporin derivatives for the treatment of immune disorders December 23, 2008
The present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof: ##STR00001## wherein A is of the formula: ##STR00002## where Q, W, X, Y, and Z are defined herein. In a second embodiment, the present inven
7419962 3,6-bicyclolides September 2, 2008
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compoun
7414030 6-11 Bicyclic erythromycin derivatives August 19, 2008
The present invention discloses compounds of formulaes I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the
7407942 3,6-bridged 9,12-oxolides August 5, 2008
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compoun
7402568 Bicyclic 9a-azalide derivatives July 22, 2008
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned
7384922 6-11 bridged oxime erythromycin derivatives June 10, 2008
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
7384921 Polymorphic forms of 6-11 bicyclic ketolide derivatives June 10, 2008
The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polym
7368452 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors May 6, 2008
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds
7312201 Tetracyclic bicyclolides December 25, 2007
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
7291602 11,12-lactone bicyclolides November 6, 2007
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
7276487 9a, 11-3C-bicyclic 9a-azalide derivatives October 2, 2007
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compound
1 2










 
 
  Recently Added Patents
Organic electroluminescence device
Method of fabricating semiconductor light emitting device
Local call local switching at handover
Debris tray
Case for electronic device
Automated pizza preparation and vending system
Fuel cell system with mechanical check valve
  Randomly Featured Patents
Hinged strut construction
Device and method for controlling radio mobile terminal connected to hands-free kit
Mass production auditory canal hearing aid
Fruit-shaped fruit fly trap
Blade for a hockey stick
Method and apparatus for minimizing axial friction forces in a cylinder-piston shock absorber
Mixed media reality brokerage network with layout-independent recognition
Adjustable water-fillable exercise weights
Method for fabricating a flexible and reinforced tubing
Method of testing cache memories used for an information processing apparatus